Summary CD55 is a protein that protects cells from complement-mediated attack. 791Tgp72 is an antigen which has been used succesfully as a target for both tumour imaging and cancer vaccines. 791Tgp72 has recently been identified as CD55. Quantitative expression of CD55 in the tumour environment was therefore studied. Tumour cells showed a 4-100-fold increase in CD55 cell surface expression when compared to normal cells. Immunohistochemical staining of colorectal tumours also revealed high expression of CD55 in the stroma. To examine the source of this stromal CD55 the ability of both epithelial cells and endothelial cells to produce extracellular CD55 was measured. Tumour cell lines deposit CD55 into their extracellular matrix (ECM) in direct proportion to their cell surface expression. In contrast the ECM from HUVEC cells contained large amounts of CD55 despite expressing low levels of CD55 on their cell surface. Furthermore expression of CD55 on HUVEC cells was increased by exposure to VEGF. Although it remains unclear why CD55 is upregulated in the tumour environment its high level of expression on tumour cells and associated endothelium may explain why it is a good target for both imaging and immunotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com Keywords: CD55 (DAF), tumour expression; endothelium; stroma; vascular endothelial growth factor (VEGF) 80Received 27 September 1999 Revised 3 February 2000 Accepted 15 March 2000 Correspondence to : LG Durrant British Journal of Cancer (2001) 84(1), 80-86 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1570, available online at http://www.idealibrary.com on http://www.bjcancer.com and tumour-conditioned medium or VEGF (10-300 µg ml -1 : Zeneca, Alderley Park, UK) respectively for 48 h prior to harvesting the HUVECs. Tumour-conditioned media was derived from the MDA 231 breast cancer cell line. These were grown to confluence and the media replaced with serum free M199:Hams F12 medium. Following 24 h incubation the resultant conditioned media was filtered for use with the HUVEC. Fresh media was used to culture the control HUVECs. Freshly resected tumours were finely minced and dissociated in collagenase (0.05%; Boehringer Mannheim) and DNase (0.1%; Boehringer Mannheim) for 1 h at 37˚C. Monoclonal antibodiesMonoclonal antibodies 791T/36 (IgG2b anti-791Tgp72;Embleton et al, 1981), BRIC 216 (IgG1 anti-SCR 3 of CD55; Tate et al, 1989), BRIC 220 (IgG1 anti-SCR 1 of CD55; Tate et al, 1989), BRIC 110 (IgG1 anti-SCR 2 of CD55; Spring et al, 1987;Coyne et al, 1992) have been reported previously. BRIC 229 and E4.3 (Sparrow and Mckenzie, 1983) recognize CD59 and CD46 respectively. The BRIC antibodies were purchased from the Blood Group Reference laboratory (Bristol, UK). Normal mouse IgG (Sigma, Dorset, UK) and 708 monoclonal antibody (IgG2b) was used as negative control antibodies. Indirect immunofluorescenceCell lines were incubated with monoclonal antibody for 1 h at 4˚C. Cells were washed twice in fresh media containing 1% FCS and then incubat...
Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.
Purpose: CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration.Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown. Experimental Design: We conducted a phase I study of CpG-ODN (1018 ISS) given as a vaccine adjuvant with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce T-cell immunity to a peptide vaccine from the tumor-associated antigen hTERT. Results: The adjuvant effect was limited; only 1of 16 patients showed a high-frequency hTERTspecific tetramer CD8 + T-cell response. However, CpG-ODN induced marked, transient peripheral blood lymphopenia. Biopsies showed dense lymphocytic infiltration at the vaccine site clustered around activated PDC. In vitro, CpG-ODN-treated PDC induced T-cell migration, showing that CpG-ODN stimulation of human PDC was sufficient to chemoattract Tcells. Conclusions: Our results show that (a) CpG-ODN with GM-CSF may not be an effective adjuvant strategy for hTERT peptide vaccines but (b) GM-CSF/CpG-ODN causes a PDC-mediated chemokine response that recruits T-cellmigration to the peripheral tissues.These findings suggest a noveltherapeuticrole for targetedinjections of CpG-ODN to directlymphocytemigrationto specific sitessuchasthetumorbed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.